^○Nobumitsu Hanioka ¹, Naoki Kishi ², Akane Takasuka ², Yuki Kokawa ², Takashi Isobe ¹, Manabu Suno ² (1.Department of Biochemical Toxicology, Yokohama University of Pharmacy, 2.Faculty of Pharmaceutical Sciences, Okayama University)

^○Mikako Torii , Tomoko Yamaguchi , Mikiko Otsuka , Tomoko Koshikawa , Tetsuya Kaneko , Hiroshi Iwata , Yasuo Takamatsu (Drug Metabolism and Pharmacokinetics Group, Drug Metabolism and Analysis Department, Nonclinical Research Center, Drug Development Service Segment, LSI Medience Corporation)

^○Ayumi Kurita ¹, Yuu Miyauchi ¹, Peter I. Mackenzie ², Hideyuki Yamada ¹, Yuji Ishii ¹ (1.Grad. Sch. Pharmaceut. Sci., Kyushu University, 2.Dep. Clin. Pharmacol., Flinders University)

^○Natsuki Egoshi ¹, Kousuke Kinoshita ¹, Hiroki Koba ¹, Shin-ichi Ikushiro ², Kiyoshi Nagata ³, Yasushi Yamazoe ⁴, Peter I Mackenzie ⁵, Hideyuki Yamada ¹, Yuji Ishii ¹ (1.Grad. Sch. Pharmaceut. Sci., Kyushu Univ., 2.Fac. Eng., Toyama Prefectural Univ., 3.Tohoku Pharmaceut. Univ., 4.The Cabinet Office, Government of Japan, 5.Dep. Clin., Pharmacol., Flinders Univ.)

^○Tsutomu Sakuma , Akiko Kubota , Shinpei Endo , Satomi Ikematsu , Yuki Kawasaki , Nobuo Nemoto , Hiroaki Sakurai (Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama)

^○Mana Yamazaki ¹, Kaoru Kobayashi ¹, Yasuhiro Kazuki ^2,3, Shoko Takehara ³, Mari Hashimoto ¹, Mitsuo Oshimura ³, Kan Chiba ¹ (1.Laboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Chiba University, 2.Graduate School of Medical Science, Tottori University, 3.Chromosome Engineering Research Center, Tottori University)

^○Yoko Jinma , Jun Terashima , Wataru Habano , Shogo Ozawa (School of Pharmacy Iwate Medical University)

^○Tomoyuki Ohe ¹, Yumina Kitagawara ¹, Kumiko Tachibana ¹, Yuki Fujita ¹, Kyoko Takahashi ¹, Shigeo Nakamura ², Tadahiko Mashino ¹ (1.Faculty of Pharmacy, Keio University, 2.Nippon Medical School)

^○Shuichi Sekine ¹, Maho Shirakawa ¹, Tomoyuki Sato ¹, Masahiro Segawa ¹, Yumina Kitagawara ², Yuki Fujita ², Tomoyuki Ohe ², Tadahiko Mashino ², Kousei Ito ¹ (1.Department of Biopharmaceutics, Graduate school of pharmaceutical sciences, Chiba University, 2.Department of Bioorganic and Medicinal Chemistry, Faculty of Pharmacy, Keio University)

^○Tetsuro Araki ^1,3, Norihiko Iwazaki ^2,4, Keisuke Nagata ^2,5, Masato Ohbuchi ^2,5, Hiroyuki Moriguchi ^2,5, Makiko Motoi ^2,6, Raku Shinkyo ^2,6, Sakae Sakamoto ^2,7, Yumiko Iwase ^2,3,4, Naoki Ishiguro ^2,8 (1.Consortium for Safety Assessment using Human iPS Cells / Asahi Kasei Pharma Corporation, 2.Consortium for Safety Assessment using Human iPS Cells, 3.Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association, 4.Mitsubishi Tanabe Pharma Corporation, 5.Astellas Pharma Inc.)

^○Naoki Cho , Kaoru Kobayashi , Mina Yoshida , Kan Chiba (Laboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Chiba University)

^○Seiichi Ishida , Shinichiro Horiuchi , Yukie Kuroda , Riho Ishida , shoko Uchida , Su-Ryang Kim , Yuko Sekino (Division of pharmacology, National Institute of Health Sciences)

^○Shun Saito , Yuma Shirasaki , Miki Nakajima , Takeo Nakanishi , Ikumi Tamai (Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University)

^○Rina Akahira , Zachary YC LIN , Kenichi Tamura , Tomohisa Watanabe , Mitsuru Inamura (ReproCELL Inc)

^○Shun Hayashi , Hidenori Matsushita , Naoyuki Sawada , Masashi Yabuki (Preclinical Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd.)

^○Keisuke Goda , Akio Kobayashi , Tadakazu Takahashi , Toshiyuki Shoda , Hideyuki Kuno , Shoichiro Sugai (JAPAN TOBACCO INC. Central Pharmaceutical Research Institute, Toxicology Research Laboratories)

^○Takeshi Susukida , Shuichi Sekine , Mayuka Nozaki , Mayuko Tokizono , Kousei Ito (Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University)

^○Chinami Nekomoto , Masashi Kawami , Ryoko Yumoto , Mikihisa Takano (Graduate School of Biomedical & Health Sciences, Hiroshima University)

^○Yasuhiro Masubuchi , Ryohei Nagai , Hiroki Hayashi (Faculty of Pharmaceutical Sciences, Chiba Institute of Science)

^○Yuki Enoki ¹, Hiroshi Watanabe ¹, Riho Arake ¹, Yuna Tominaga ¹, Ryusei Sugimoto ¹, Yu Ishima ¹, Motoko Tanaka ², Kazutaka Matsushita ², Masafumi Fukagawa ³, Masaki Otagiri ⁴ (1.Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 2.Department of Nephrology, Akebono Clinic, 3.Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 4.Faculty of Pharmaceutical Sciences, Sojo University)

^○Kazuko Nishimura ¹, Shinko Hata ², Tsutomu Hashimoto ³, Tamiki Mori ³, Noriko Inoue ⁴, Satomi Sasahara ⁴, Hiroko Shigemizu ⁴, Takahiro Nakamura ⁵, Tatsuki Nomura ⁵, Yoshinobu Yokota ⁵ (1.Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 2.Ig-M Corporation, 3.LSI Medience Corporation, 4.CMIC Pharma Science Co., Ltd., 5.Shin Nippon Biomedical Laboratories, Ltd.)

^○Hiroko Arai ¹, Yoshihisa Hiroe ², Xiaomi Xin ¹, Taketoshi Kanda ¹, Isao Yanagisawa ¹ (1.Shiseido Co., Ltd., 2.Shiseido Irica Technology INC.)

^○Seiji Mitani ¹, Kazuo Takayama ^1,2,3, Masashi Tachibana ¹, Huminori Sakurai ¹, Hiroyuki Mizuguchi ^1,2,3,4 (1.Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, 2.Laboratory of Hepatocyte Regulation, National Institutes of Biomedical Innovation, Health and Nutrition, 3.iPS Cell-based Research Project on Hepatic Toxicity and Metabolism, Graduate School of Pharmaceutical Sciences, Osaka University, 4.Global Center for Medical Engineering and Informatics, Osaka University)

^○Zachary YC Lin , Kenichi Tamura , Rina Akahira , Tomohisa Watanabe , Mitsuru Inamura (ReproCELL Inc.)

^○1, Yasuhiro Yamato ¹, Sharon L. Ripp ², Anne M. Ryan ³, Susan I. Hurst ², Marjorie Peraza ⁴ (1.Drug Safety Research & Development, Pfizer Japan Inc., 2.Pharmacokinetics, Dynamics & Metabolism, Pfizer, Groton, CT, 3.Drug Safety Research & Development, Pfizer, Groton, CT, 4.Drug Safety Research & Development, Pfizer, Andover, MA)